Front Row Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Front Row Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.54K	Hold	2	–	–	﹤0.01%	510
2025 Q4	$1.54K	Hold	2	–	–	﹤0.01%	500
2025 Q3	$1.13K	Sell	2 -1	-33%	-$565	﹤0.01%	507
2025 Q2	$1.57K	Sell	3 -1	-25%	-$558	﹤0.01%	482
2025 Q1	$2.54K	Hold	4	–	–	﹤0.01%	442
2024 Q4	$2.85K	Hold	4	–	–	﹤0.01%	430
2024 Q3	$4.21K	Hold	4	–	–	﹤0.01%	417
2024 Q2	$4.2K	Hold	4	–	–	﹤0.01%	759
2024 Q1	$3.85K	Hold	4	–	–	﹤0.01%	768
2023 Q4	$3.51K	Hold	4	–	–	﹤0.01%	393
2023 Q3	$3.29K	Hold	4	–	–	﹤0.01%	750
2023 Q2	$3K	Hold	4	–	–	﹤0.01%	770
2023 Q1	$3K	Buy	+4	New	+$3.02K	﹤0.01%	780
2022 Q4	–	Sell	-4	Closed	-$3K	–	930
2022 Q3	$3K	Hold	4	–	–	﹤0.01%	765
2022 Q2	$2K	Hold	4	–	–	﹤0.01%	840
2022 Q1	$3K	Hold	4	–	–	﹤0.01%	816
2021 Q4	$3K	Hold	4	–	–	﹤0.01%	841
2021 Q3	$2K	Hold	4	–	–	﹤0.01%	875
2021 Q2	$3K	Hold	4	–	–	﹤0.01%	833
2021 Q1	$2K	Sell	4 -31	-89%	-$15.1K	﹤0.01%	876
2020 Q4	$17K	Hold	35	–	–	0.01%	412
2020 Q3	$18K	Hold	35	–	–	0.01%	393
2020 Q2	$22K	Sell	35 -1	-3%	-$568	0.01%	330
2020 Q1	$19K	Sell	36 -2	-5%	-$825	0.01%	342
2019 Q4	$14K	Hold	38	–	–	0.01%	394
2019 Q3	$11K	Buy	38 +4	+12%	+$1.18K	0.01%	426
2019 Q2	$11K	Sell	34 -3	-8%	-$999	0.01%	422
2019 Q1	$15K	Buy	37 +4	+12%	+$1.65K	0.01%	381
2018 Q4	$12K	Hold	33	–	–	0.01%	373
2018 Q3	$12	Hold	33	–	–	0.01%	398
2018 Q2	$12	Buy	33 +6	+22%	+$1.88K	0.01%	422
2018 Q1	$9K	Buy	+27	New	+$9.39K	0.01%	458

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Front Row Advisors's REGN Position: Q1 2026 in Review

Front Row Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 2 shares worth $1.54K. The position accounts for ﹤0.01% of the portfolio, ranked #510.

Front Row Advisors first reported a position in REGN in Q1 2018 and has held it in 32 quarters since. The position peaked at $22K in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Front Row Advisors held 2 shares of Regeneron Pharmaceuticals worth $1.54K as of Q1 2026.
Front Row Advisors left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #510 holding.
Front Row Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 32 quarters since.
Front Row Advisors's Regeneron Pharmaceuticals position peaked at $22K in Q2 2020.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.